More from these Authors

• Case | HBS Case Collection | March 2019 (Revised November 2019)

  Gilead: Hepatitis C Access Strategy (A) (Abridged)

  V. Kasturi Rangan, Vikram Rangan and David E. Bloom

  Gilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of this was accomplished through generic licensing, which brought a $10,000/year treatment regimen down to $100! Should the company replicate that strategy for Hepatitis C? If so, how would its US Healthcare customers, who were paying $84,000 per patient, react? On the other hand, Gilead had to balance the interests of its shareholders, who paid $11 billion for an acquisition that led to the new Hepatitis C drug.

  Keywords: healthcare; Pharmaceuticals; pricing; Access to care;

  Citation:

  Rangan, V. Kasturi, Vikram Rangan, and David E. Bloom. "Gilead: Hepatitis C Access Strategy (A) (Abridged)." Harvard Business School Case 519-077, March 2019. (Revised November 2019.)  View Details

  CiteView DetailsEducators

  Related

• Case | HBS Case Collection | September 2019 (Revised November 2019)

  Pinduoduo

  Feng Zhu, Krishna G. Palepu, Bonnie Yining Cao and Dawn H. Lau

  Founded in 2015 by serial entrepreneur, Colin Huang, Pinduoduo Inc. (PDD) had become China’s fastest-growing e-commerce platform in history. PDD pioneered a new approach to online shopping that allowed shoppers to share products, invite friends to form shopping teams, and purchase together at discounted prices. The company’s rapid development helped it debut on the Nasdaq in July 2018, only three years after its inception. The fast growth was partly boosted by PDD’s heavy investment in marketing and branding, such as through coupons and promotions. How should the company make its competitive advantages more sustainable? Could its business model be replicated outside China?

  Citation:

  Zhu, Feng, Krishna G. Palepu, Bonnie Yining Cao, and Dawn H. Lau. "Pinduoduo." Harvard Business School Case 620-040, September 2019. (Revised November 2019.)  View Details

  CiteView DetailsEducatorsPurchase

  Related

• Case | HBS Case Collection | August 2019 (Revised November 2019)

  Transforming Hindustan Unilever

  Krishna G. Palepu and Rachna Tahilyani

  In October 2013, when Mehta had taken over the reins of Unilever’s business in India and the larger South Asia region, HUL had been going through a difficult time. Caught in the midst of a weakening economy, falling consumer spending and increasing competition, growth at the firm had slowed. HUL was underperforming not only the market index but also the FMCG index. At the same time, HUL was struggling with many internal woes, ranging from slow market responsiveness to a higher cost structure. The next quarter had not brought any relief. With the external situation worsening, Mehta wondered what changes he needed to make to ensure consistent, competitive and profitable growth at HUL. The case is accompanied by a video in which the CEO outlines his thinking, and the choices he made. The video can be used in class as the class discussion unfolds to bring closure to the discussion, and to brief the class on what actions were taken.

  Keywords: Change Management; Transformation; Leading Change; Performance Improvement; Consumer Products Industry; India;

  Citation:

  Palepu, Krishna G., and Rachna Tahilyani. "Transforming Hindustan Unilever." Harvard Business School Case 120-022, August 2019. (Revised November 2019.)  View Details

  CiteView DetailsEducatorsPurchase

  Related